Skip to content
Open access

T-cell engager bispecific antibodies enable T cells to eliminate Multiple Myeloma by targeting tumor CD38 in combination with PD-L1

Aug 2026 · Cell Death & Disease · 0 citations

TL;DR

In vitro data revealed that a bispecific antibody simultaneously engaging PD-L1 and CD38 exhibited markedly enhanced antitumor efficacy—even under conditions of reduced CD38 surface expression on MM cells.

Abstract

Bispecific antibodies have gradually been applied in the treatment of multiple myeloma(MM). The combination of bispecific antibodies targeting CD3 and CD28 mimics the dual-signaling system (antigen signaling and co-stimulatory signaling) of natural T cell activation, thereby significantly enhancing the anti-tumor response of T cells. CD38, a transmembrane glycoprotein, is highly expressed on MM cells and serves as an important surface marker. Meanwhile, PD-L1, an immunosuppressive molecule, is associated with poor prognosis in MM patients. Leveraging these biological insights, this study systematically evaluated the capacity of bispecific antibodies to eliminate MM cells via T-cell activation, employing comprehensive in vitro functional assays and in vivo murine models. Notably, in vitro data revealed that a bispecific antibody simultaneously engaging PD-L1 (to counteract immune suppression) and CD38 (to direct T-cell cytotoxicity) exhibited markedly enhanced antitumor efficacy—even under conditions of reduced CD38 surface expression on MM cells. Nevertheless, the translational relevance of this combinatorial mechanism requires further validation in preclinical in vivo settings.

Read PDF

Similar papers

Review Open access Sep 2026

Effector-cell-engaging bispecific antibodies for cancer therapeutics: engineering precision immunity.

This review outlines the evolution of effector-cell-engaging bsAb formats, such as BiTEs, DARTs, TandAbs and IgG-like constructs, along with engineering strategies to enhance Fc function, valency, half-life, safety and efficacy.

A. Gholap, P. Khuspe, Darshana Morankar et al. · 0 citations
Open access Aug 2026

Autocrine PD-1-blocking nanobodies enhance the antitumor efficacy of TCR-like CAR-T cells by attenuating t cell exhaustion

In the SKOV3-A2 solid tumor xenograft model, WT1-CAR-Nb T cells mediated superior tumor growth control and significantly prolonged overall survival, which was closely correlated with enhanced intratumoral T cell infiltration and persistent in vivo expansion of engineered T cells.

Wan-Jun He, Kai Cui, Yi-Wei Zeng et al. · 0 citations
Open access Oct 2026

Combating CD24 to overcome CD19 CAR-T resistance via induction of innate and adaptive immunity in B-cell malignancies.

This study developed a CD24’sAb and CXCR3-armed CD24 CAR-T cells, both exhibiting potent antitumor activity in lymphoma and leukemia models, and engineered a dual-specific, dual-functional CD19 CAR-T that secretes a CD24 bispecific T-cell engager (CD24 BiTE), enabling simultaneous targeting of CD19 and CD24 to address...

Qing Yin, Jing Gao, Xian-Gao Huang et al. · 0 citations
Open access Oct 2026

53L10 T-cell engager tribody for immunotherapy of multiple solid tumors

Cancer immunotherapy with immune checkpoint inhibitors (ICIs), i.e., antibodies targeting inhibitory ICs, such as PD-1, PD-L1, and CTLA-4, have successfully revolutionized cancer treatment. One of the most promising cancer immunotherapies is based on bi-specific T-cell engagers that simultaneously bind with one arm to...

M. Passariello, M. Belardo, Toshikazu Inoue et al. · 0 citations
Open access Sep 2026

29 Engineering CD16-Enhanced Stem Cell–Derived Universal NKT Cells to Potentiate Anti-CD70 Therapy in Renal Cell Carcinoma

CD16HSC-NKT cells are established as a versatile and scalable cellular platform that synergizes with cusatuzumab to enhance therapeutic efficacy against RCC, and represent a promising approach to overcoming current limitations of monoclonal antibody therapy and advancing next-generation immunotherapies for solid tumors...

Yan-Ruide Li, Yi-Chen Zhu, Yu-Ning Chen et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.